|
Acetyl L Carnitine Molecule
|
Acetyl L Carnitine Molecule
Cancer
Cancer Treatment
Fight cancer
Antioxidant
|
[Left Mouse Button And Drag To Manually Rotate The Molecule]
|
|
Fatigue is the most commonly reported symptom in patients with cancer, with a prevalence of over 60% reported in the majority of studies. Clinical trials that assessed pharmacologic agents for the treatment of cancer related fatigue include Acetyl L Carnitine(ALC) (Carroll, 2007).
- Antioxidant
- Neuroprotector and induces neurotrophy
- Increases mitochondrial metabolism
- Stabilizes intracellular membrane
- Improves fatigue symptoms
- Phase I- 1

Lack of sufficient levels of ALC is among the postulated causes of fatigue, a highly prevalent symptom in the multiple sclerosis (MS) population, which has a serious impact on patients' quality of life. Deficiency of carnitine may play a role by reducing energy production through fatty acid oxidation and numerous MS therapies can induce fatigue syndrome. For 63% of patients treated with immunosuppressive or immunomodulatory therapies, oral ALC decreased fatigue intensity, especially in patients treated with cyclophosphamide and interferon beta (Lebrun, 2006).
|